-
Mashup Score: 0ESMO 2021: Role of Serum Biomarkers of Bone Metabolism in mCRPC Patients Treated with Radium-223: PRORADIUM Study Final Results - 2 year(s) ago
ESMO 2021 final results of PRORADIUM, role of serum biomarkers of bone metabolism in mCRPC patients treated with radium-223, alpha-emitter bone targeted therapy for mCRPC,
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 49
Original Article from The New England Journal of Medicine — Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer
Source: New England Journal of MedicineCategories: Latest Headlines, Oncologists1Tweet-
Finally super #DESTINYbreast03 data presented at #ESMO21 are out in @NEJM: #TrastuzumabDeruxtecan is the new standard 2nd line therapy in #HER2+ advanced #BreastCancer..congrats (and thanks) @JavierCortesMD et al for this terrific trial! @OncoAlert #bcsm https://t.co/3XTM5PQ8v1
-
-
Mashup Score: 2
ESMO 2021 RORADIUM (NCT02925702) study, a prospective observational study of mCRPC patients treated with standard-of-care Radium-223, PRORADIUM examining the effect of germline mutations on outcomes for patients treated with radium-223, ALSYMPCA, radium-223, radium-223 for prostate cancer
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
#PRORADIUM: Prospective analysis of the impact of germline mutations in homologous recombination genes on the response to radium-223 for #mCRPC. Presented by @Ecastromarcos @CNIOStopCancer. #ESMO21 written coverage by @WallisCJD @UofT on UroToday > https://t.co/uqYcmtTmsR @myESMO https://t.co/AXiaBaC3IQ
-
-
Mashup Score: 0ESMO Summit Africa 2022 | OncologyPRO - 2 year(s) ago
OncologyPRO is the home of ESMO’s educational & scientific resources, with exclusive content for ESMO members such as ESMO’s Congresses webcasts,
Source: oncologypro.esmo.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
ESMO Summit Africa 2022 resources now available. Created for #oncology professionals in Africa by intl. & local key opinion leaders, the event focused on several key disease sites, putting into context most significant tx advances presented at #ESMO21 ➡️ https://t.co/PDeGPT1XzA https://t.co/ukDUCCpeFh
-
-
Mashup Score: 6
ESMO 2021 RORADIUM (NCT02925702) study, a prospective observational study of mCRPC patients treated with standard-of-care Radium-223, PRORADIUM examining the effect of germline mutations on outcomes for patients treated with radium-223, ALSYMPCA, radium-223, radium-223 for prostate cancer
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
#PRORADIUM: Prospective analysis of the impact of germline mutations in homologous recombination genes on the response to radium-223 for #mCRPC. Presented by @Ecastromarcos @CNIOStopCancer. #ESMO21 written coverage by @WallisCJD @UofT on UroToday > https://t.co/uqYcmtTmsR @myESMO https://t.co/OWyCyIwEJF
-
-
Mashup Score: 5Treatment Advances in HR+/HER2- MBC - 2 year(s) ago
Final takeaways from a discussion on best practices treating HR+/HER2- metastatic breast cancer with CDK4/6 inhibitors and PI3K therapies based on data presented at ESMO 2021.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
WATCH: Experts give takeaways from a discussion on best practices treating HR+/HER2- metastatic breast cancer with CDK4/6 inhibitors and PI3K therapies based on data presented at #ESMO21 @Neil_Iyengar @BCJoyceO @drsarahsam @DukeCancer @sloan_kettering https://t.co/oahGzWRWK8 https://t.co/0ffbRWtEJN
-
-
Mashup Score: 0ESMO 2021: Role of Serum Biomarkers of Bone Metabolism in mCRPC Patients Treated with Radium-223: PRORADIUM Study Final Results - 2 year(s) ago
ESMO 2021 final results of PRORADIUM, role of serum biomarkers of bone metabolism in mCRPC patients treated with radium-223, alpha-emitter bone targeted therapy for mCRPC,
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Role of serum biomarkers of bone metabolism in #mCRPC patients treated with radium-223: #PRORADIUM study final results. Presentation by Nuria Romero-Laorden, MD, PhD @CNIOStopCancer. #ESMO21 written coverage by @zklaassen_md @GACancerCenter > https://t.co/aF3x4bg9RU @myESMO https://t.co/ttJvG9a4pm
-
-
Mashup Score: 0Practice-Changing and Emerging Treatment Strategies in Metastatic Urothelial Carcinoma - Guru Sonpavde - 2 year(s) ago
Guru Sonpavde joins Ashish Kamat sharing takeaways from the 2021 ESMO meeting starting with practice-changing or practice reaffirming studies, followed by other emerging drugs and data. Dr. Sonpavde highlighted the landmark phase 3 EV-301 study that led to the approval of enfortumab vedotin in post-platinum and PD-1 inhibitor-treated patients with metastatic urothelial carcinoma. Among the…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
Practice-changing and emerging treatment strategies in metastatic #UrothelialCarcinoma. @sonpavde @DanaFarber joins @UroDocAsh @MDAndersonNews sharing takeaways from the #ESMO21 annual meeting. #WatchNow on UroToday > https://t.co/y6hysqCR5D @myESMO https://t.co/YNQtbedi5B
-
-
Mashup Score: 1
ESMO 2021 RORADIUM (NCT02925702) study, a prospective observational study of mCRPC patients treated with standard-of-care Radium-223, PRORADIUM examining the effect of germline mutations on outcomes for patients treated with radium-223, ALSYMPCA, radium-223, radium-223 for prostate cancer
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
#PRORADIUM: Prospective analysis of the impact of germline mutations in homologous recombination genes on the response to radium-223 for #mCRPC. Presented by @Ecastromarcos @CNIOStopCancer. #ESMO21 written coverage by @WallisCJD @UofT on UroToday > https://t.co/uqYcmtTmsR @myESMO https://t.co/dg0s76N76U
-
-
Mashup Score: 3Benjamin Besse on NSCLC A Vaccine Under Study to Treat Advanced Disease - The ASCO Post - 2 year(s) ago
ESMO Congress 2021 Benjamin Besse, MD, PhD, of the Institut Gustave Roussy, discusses final phase III findings from the Atalante-1 trial, which explored the question of whether the OSE2101 vaccine is more beneficial than standard treatment for patients with HLA-A2–positive non–small cell lung cancer after immune checkpoint inhibitors…
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Benjamin Besse, MD, PhD, on NSCLC: A Vaccine Under Study to Treat Advanced Disease https://t.co/DDZxnWDjmB #LCSM #ESMO21 #ESMO2021 @BenjaminBesseMD @GustaveRoussy https://t.co/WPwo43A5DH
-
Role of serum biomarkers of bone metabolism in #mCRPC patients treated with radium-223: #PRORADIUM study final results. Presentation by Nuria Romero-Laorden, MD, PhD @CNIOStopCancer. #ESMO21 written coverage by @zklaassen_md @GACancerCenter > https://t.co/aF3x4bg9RU @myESMO https://t.co/IYoJcs2WOb